European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

HMA / EMA multistakeholder AI and Data forum: Build trustworthy AI on strong data foundations, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 12 November 2026 to 13 November 2026

Submitted by Anonymous (not verified) on 10 September 2026 - 16:25

HMA / EMA multistakeholder AI and Data forum: Build trustworthy AI on strong data foundations, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 12 November 2026 to 13 November 2026

Human medicines European public assessment report (EPAR): Xeljanz, tofacitinib, Date of authorisation: 22/03/2017, Revision: 38, Status: Authorised

Submitted by Anonymous (not verified) on 10 September 2026 - 15:22

Human medicines European public assessment report (EPAR): Xeljanz, tofacitinib, Date of authorisation: 22/03/2017, Revision: 38, Status: Authorised

Human medicines European public assessment report (EPAR): Uzpruvo, ustekinumab, Date of authorisation: 05/01/2024, Revision: 12, Status: Authorised

Submitted by Anonymous (not verified) on 10 September 2026 - 15:06

Human medicines European public assessment report (EPAR): Uzpruvo, ustekinumab, Date of authorisation: 05/01/2024, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Zoledronic acid Mylan, zoledronic acid, Date of authorisation: 23/08/2012, Revision: 18, Status: Authorised

Submitted by Anonymous (not verified) on 10 September 2026 - 14:00

Human medicines European public assessment report (EPAR): Zoledronic acid Mylan, zoledronic acid, Date of authorisation: 23/08/2012, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Tagrisso, osimertinib, Date of authorisation: 01/02/2016, Revision: 25, Status: Authorised

Submitted by Anonymous (not verified) on 10 September 2026 - 13:45

Human medicines European public assessment report (EPAR): Tagrisso, osimertinib, Date of authorisation: 01/02/2016, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR): Moventig, naloxegol, Date of authorisation: 07/12/2014, Revision: 20, Status: Authorised

Submitted by Anonymous (not verified) on 10 September 2026 - 13:28

Human medicines European public assessment report (EPAR): Moventig, naloxegol, Date of authorisation: 07/12/2014, Revision: 20, Status: Authorised

First European Medicines Agency (EMA) - International Society for Cell and Gene Therapy (ISCT) bilateral meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, from 5 October 2026, 15:30 (CEST) to 5 October 2026, 17:30 (CEST)

Submitted by Anonymous (not verified) on 10 September 2026 - 12:44

First European Medicines Agency (EMA) - International Society for Cell and Gene Therapy (ISCT) bilateral meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, from 5 October 2026, 15:30 (CEST) to 5 October 2026, 17:30 (CEST)

Fifth European Medicines Agency (EMA) - Vaccines Europe bilateral meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, from 26 October 2026, 14:00 (CET) to 26 October 2026, 16:00 (CET)

Submitted by Anonymous (not verified) on 10 September 2026 - 12:41

Fifth European Medicines Agency (EMA) - Vaccines Europe bilateral meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, from 26 October 2026, 14:00 (CET) to 26 October 2026, 16:00 (CET)

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness